Log in

Kaleido Biosciences Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/18/2020 09:30 PM ET)
Today's Range
Now: $5.90
50-Day Range
MA: $6.78
52-Week Range
Now: $5.90
Volume523,000 shs
Average Volume155,035 shs
Market Capitalization$209.73 million
P/E RatioN/A
Dividend YieldN/A
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:KLDO



Sales & Book Value

Annual SalesN/A



Market Cap$209.73 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
0.00 (0.00 %)
(As of 09/18/2020 09:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

How has Kaleido Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KLDO shares have increased by 6.5% and is now trading at $5.90.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Kaleido Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kaleido Biosciences

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Kaleido Biosciences

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences Inc (NASDAQ:KLDO) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.59). The firm had revenue of $0.25 million for the quarter.
View Kaleido Biosciences' earnings history

What price target have analysts set for KLDO?

2 equities research analysts have issued twelve-month price objectives for Kaleido Biosciences' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Kaleido Biosciences' share price to reach $8.00 in the next year. This suggests a possible upside of 35.6% from the stock's current price.
View analysts' price targets for Kaleido Biosciences

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Fulcrum Therapeutics (FULC), Precision BioSciences (DTIL), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX) and Heron Therapeutics (HRTX).

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:
  • Mr. Michael W. Bonney, Exec. Chair (Age 62, Pay $397.5k)
  • Ms. Alison Lawton, CEO, Pres & Director (Age 59, Pay $1.04M)
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 39, Pay $35k)
  • Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 41, Pay $464.81k)
  • Dr. Katharine Knobil M.D., Chief Medical Officer and Head of R&D (Age 55, Pay $868.03k)

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Flagship Pioneering Inc. (54.47%), FMR LLC (7.64%), Federated Hermes Inc. (1.41%), Monashee Investment Management LLC (0.42%), Nuveen Asset Management LLC (0.16%) and Tudor Investment Corp Et Al (0.12%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship and Ventures Fund V LP Flagship.
View institutional ownership trends for Kaleido Biosciences

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors.
View insider buying and selling activity for Kaleido Biosciences

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was bought by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., Federated Hermes Inc., FMR LLC, Monashee Investment Management LLC, Tudor Investment Corp Et Al, Bessemer Group Inc., Nuveen Asset Management LLC, and Jacobs Levy Equity Management Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship, and Ventures Fund V LP Flagship.
View insider buying and selling activity for Kaleido Biosciences

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $5.90.

How big of a company is Kaleido Biosciences?

Kaleido Biosciences has a market capitalization of $209.73 million. Kaleido Biosciences employs 91 workers across the globe.

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.